It is being studied, but it does not currently have the same FDA-approved prescribing status as semaglutide or tirzepatide for weight loss
For complete directions for use and safety information see product label
, ,
Physicians who prescribe GLP-1 therapies are frequently asked about compounded semaglutide, and board-certified obesity medicine specialists are best positioned to explain the clinical, regulatory, and quality distinctions between compounded and branded formulations
If a patient is interested in starting a GLP-1, health care professionals should follow the patients lead, ask them what they know about the medication and provide evidence-based information on the therapy, Ihlenfeld said
Due to the pleiotropic effects of GLP-1RAs, they become the basis of a new therapeutic strategy that affects both metabolic and neuropsychiatric aspects, which is fundamentally important for the treatment of comorbid diseases